April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Variations In The Morphology Of The Retinal Vessels Following Intravitreal Anti-VEGF Therapy For Treatment Requiring Retinopathy of Prematurity
Author Affiliations & Notes
  • Maria A. Martinez-Castellanos
    Retina and Vitreous, Asociacion Para Evitar la Ceguera, Mexico, Mexico
  • Virgilio Morales-Canton
    Retina Department, Asociacion para Evitar la Ceguera, Mexico, Mexico
  • Mario J. Saravia
    Ophthalmology /Retina, Hospital Austral, Buenos Aires, Argentina
  • Robison V. Chan
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Hugo Quiroz-Mercado
    Ophthalmology, Denver Health Medical Center, Denver, Colorado
  • Footnotes
    Commercial Relationships  Maria A. Martinez-Castellanos, None; Virgilio Morales-Canton, None; Mario J. Saravia, None; Robison V. Chan, None; Hugo Quiroz-Mercado, None
  • Footnotes
    Support  St. Giles Foundation
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3129. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maria A. Martinez-Castellanos, Virgilio Morales-Canton, Mario J. Saravia, Robison V. Chan, Hugo Quiroz-Mercado; Variations In The Morphology Of The Retinal Vessels Following Intravitreal Anti-VEGF Therapy For Treatment Requiring Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3129.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To describe the retinal vascular morphology in eyes that were treated with intravitreal bevacizumab (IB) as monotherapy for retinopathy of prematurity (ROP) stage 3

Methods: : Prospective, nonrandomized case series. We included six patients (12 eyes) diagnosed with stage 3, thereshold or prethreshold ROP treated with IB. Fundus photographs and FA were obtained before and after IB treatment using a wide-field digital pediatric imaging system.

Results: : Before treatment, FA showed vascular abnormalities, including capillary nonperfusion throughout the vascularized retina, shunting in the vascularized retina, a demarcation line, and limited vessel development, new vessels leakege, and avascular periphery. After the treatment with the supression of VEGF, FA showed obliteration of abnormal new vessels, followed by involution of the neovascularization, flattening of the demarcation line and subsequent growth of vessels to the capillary-free zones. During the following weeks large areas devoid of microvessels were seen, 6 months post intravitreal injection of bevacizumab, vascular remodelling was seen with uneven spacing of the retinal capillaries and vascular loops in the areas that were previously devoid of vessels. In some patients, the retinal vessels in the far periphery never developed. Subsequently, these patients did not develop pathological neovascularization.

Conclusions: : Our study shows that even when the vascular pattern is abnormal after intravitreal anti-VEGF therapy, the creation of small vessels, the establishment of directional flow, the association with mural cells (pericytes and smooth muscle cells) and the adjustment of vascular density to meet the nutritional requirements of the retina have been accomplished. Longer follow up is needed of prospective multicenter studies to determine the safety profile for the use of IB in treatment requiring ROP.

Clinical Trial: : http://www.clinicaltrials.gov NCT00346814

Keywords: retinopathy of prematurity • drug toxicity/drug effects • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.